The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2017 | CASTOR trial update: daratumumab/bortezomib/dexamethasone is an important regimen for R/R MM
An exciting update on the CASTOR trial was presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA. Here, Katja Weisel, MD, of University of Tübingen, Tübingen, Germany, shares the results that were presented from the long-term follow-up of the CASTOR trial (NCT02136134), a comparative Phase III study that assessed the effects of administering daratumumab combined with bortezomib and dexamethasone, compared with bortezomib and dexamethasone alone, in patients with relapsed and/or refractory multiple myeloma (MM).
